News

Dr. Nathan Chen leaves OBI Pharma; Accepts New Role on Company’s Medical Advisory Board

OBI Pharma today announced that Dr. Nathan Chen has resigned …

Quick Takes on Promising New Approaches to Treating Breast Cancer

ASCO KOL interviews: Dr. Hope Rugo/Dr. James C. Paulson

OBI Pharma Presents Data for Novel Investigational OBI-822/OBI-821 in Patients with Metastatic Breast Cancer at the 2016 American Society of Clinical Oncology Annual Meeting

Results from Phase II/III Clinical Trials Show Improvement in Subset …

OBI’s Abstract at ASCO 2016: Randomized Phase 2/3 Trial of Active Immunotherapy With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer

Background: Globo H is a glycolipid that is highly expressed …

OBI Pharma to Present New Data at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Oral Presentation Highlights the Results of a Phase II/III Trial …

Company Position Statement Regarding Recent Investigation of Senior Executives

OBI Pharma strongly denies allegations of insider trading. Since March …

OBI Pharma Announces Decision By ASCO to Accept its Abstract for Oral Presentation at ASCO’S 2016 Annual Meeting

OBI Pharma, Inc. today announced that the American Society of …

OBI Pharma Reports Topline Results from OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial in Patients with Metastatic Breast Cancer

Plans to Advance to Global Phase 3 Clinical Program TAIPEI, …

OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan

OBI Eligible to Receive Milestone Payments as well as US$3.0 …